Cambridge, England And Waltham, Mass, May 17, 2023 /PRNewswire/ — Abcam plc (NASDAQ: ABCM), (“Abcam,” “Company,” “Group”) (Nasdaq: ABCMA global leader in the supply of life science research equipment today, its founder and former director, Dr. Jonathan Milner He indicated that he would take steps to call an Extraordinary General Meeting (EGM) of the company’s shareholders to elect himself as the executive chairman of the company’s board of directors.
The company is surprised that Dr. Milner decided to make this public statement in view of the ongoing discussions with him regarding the appointment of the board.
Dr. Milner first asked for re-appointment to the board. April 28, 2023He could have sought a resolution at the AGM to achieve his objective less than three weeks before and after the date of the company’s Annual General Meeting (“AGM”). The board was quick to speculate that it would return to the board, including meeting all non-executive directors within 10 days.
Dr. Milner’s request was thoroughly considered by the Nominating Committee and the entire Board of Directors. According to the traditional relationship agreement, Dr. Milner will be given the opportunity to be appointed as a member of the board and it was decided today to reach a consensus in the forum. After informing Dr. Milner that the board might appoint him, he immediately declined the call and asked to name an executive to replace the current chairman.
The company recalled that Dr. Milner gave a press release regarding this question before the board had time to respond. Despite the Board’s clear and consistent efforts to engage constructively with Dr. Milner, the Company is disappointed that it has instead resorted to aggressive tactics in trying to force the Company to accept his request.
Today, the company’s AGM ended with the shareholders voting overwhelmingly in favor of all the resolutions, and the directors received an average of 95% shareholder support.
About Abcam plc
As an innovator in reagents and tools, Abcam’s mission is to serve life science researchers worldwide to accelerate their mission. Providing tools and scientific support to the research and clinical communities, the company provides highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
A pioneer in data sharing and e-commerce in the life sciences, Abcam’s ambition is to be the most influential company in the life sciences by helping to develop global understanding of biology and disease pathogenesis, which in turn, leads to new treatments and improved health.
Abcam’s global customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the company continuously expands its portfolio to meet their needs. Transparent customer reviews and data sheets combined with industry-leading validation initiatives give researchers confidence in their results.
Established and headquartered in 1998 Cambridge, UK, the company has served customers in more than 130 countries. Abcam’s American Depositary Shares (ADS) are traded on the Nasdaq International Options Exchange (NASDAQ: ABCM).
For more information, please visit www.abcam.com Or www.abcamplc.com
This advertisement was published in Contains forward-looking statements within the meaning of the Private Securities Litigation Amendment Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “could,” “could,” “could,” “may,” “should,” “expect,” “plan,” “anticipate,” “anticipate,” “expect,” “believe,” “estimate,” “anticipate,” “potential,” “continue,” “consider,” “possible” or the negatives of such words or other synonyms, although not all forward-looking statements contain such words. They are not historical facts, nor are they guarantees of future performance. Any express or implied statements that are not historical facts contained in this announcement may be considered forward-looking statements, including, without limitation, Abcam’s portfolio and ambitions, cost optimization and efficiency initiatives, and our future results of operations and financial position. Prospects such as our 2023 outlook and 2024 performance goals are not guarantees, but involve known and unknown risks and uncertainties that may cause actual results to differ from those anticipated, including, without limitation, challenges in implementing our strategies; competitive challenges to revenue growth; the need to develop new products or improve existing products, and to adapt to major technological changes or to respond to the introduction of new products competitively; to discontinue or reduce our customers’ expenditures on research, development, production or other scientific efforts; to be unable to successfully identify or integrate acquired businesses or assets; or failure to fully realize the expected benefits of our businesses or assets; The ongoing COVID-19 pandemic continues to impact our business, including variables, and the impact it will have on our operations and supply chains. the inability to successfully use, access and maintain information systems and implement new systems to meet our changing needs; cybersecurity risks and failure to maintain the confidentiality, integrity and availability of our computer hardware, software and Internet applications and related devices and functions; inability to successfully manage our current and future growth; significant interruptions in our operations; Our products fail to meet applicable quality standards, specifications and performance standards; failure to protect and improve our brand and reputation; ability to respond to adverse geopolitical or economic changes affecting life science funding; Failure to deliver on transformational development projects; our dependence on management and highly skilled personnel and our ability to attract and retain these highly skilled personnel; And as a foreign private issuer, we are exempt from certain rules under U.S. securities laws and Nasdaq’s corporate governance rules and are permitted to provide less information to the SEC than U.S. companies, which may limit the information available to our U.S. shareholders. Depositary Shares (“ADS”); and other important factors are discussed under the heading “Risk Factors” in Abcam’s Annual Report on Form 20-F for the year ended December 31, 2022 (“Annual Report”) filed with the US Securities and Exchange Commission (“SEC”). March 20, 2023Available on the SEC website www.sec.gov, such factors may be updated from time to time in Abcam’s subsequent filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abikam disclaims any obligation or duty to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
Vice President, Investor Relations
152 Grove Street, Building 1100
Waltham, MA 02453
FTI Advisor (Media Inquiries)
Ben Atwell / Pat Tucker
Source Abcam PLC
We offer you some site tools and assistance to get the best result in daily life by taking advantage of simple experiences